Nimavat Nirav, Singh Shruti, Patel Divyang, Singh Pratibha, Hasan Mohammad Mehedi, Mandala Gowthamm, Bhangu Ranvir, Priya Aakanksha
Community Medicine, Pacific Institute of Medical Sciences, Udaipur, IND.
Pharmacology, All India Institute of Medical Sciences Patna, Patna, IND.
Cureus. 2022 Mar 14;14(3):e23146. doi: 10.7759/cureus.23146. eCollection 2022 Mar.
The coronavirus disease 2019 (COVID-19) pandemic hit the world badly with high mortality. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increased the COVID-19 burden among developed and developing countries due to the unavailability of proven treatment options. Vitamin D has many important anti-inflammatory, immunomodulator, and anti-viral functions. The present study was conducted to evaluate the relationship between Vitamin D in COVID-19.
A cross-sectional study was conducted at a tertiary care hospital in Patna, India. All the patients were enrolled during the period of 3.5 months. A chemiluminescence-based immunoassay analyzer was used to quantify Vitamin D among COVID-19 patients. The study compared Vitamin D deficiency and insufficiency among different groups, i.e., age, sex, BMI, comorbidity, etc. Diabetes and hypertension were evaluated as risk factors for mortality.
A total of 225 patients were investigated. Of these, 13.6% had Vitamin D deficiency and 38.9% had insufficiency. Vitamin D level was statistically significant among different age groups, sex, and smokers. Patients aged >60 years were 23 times more likely to have a severe illness (adjusted OR (aOR) 23.53, 95%CI 4.67-118.61), whereas those aged 40 to 60 years were 11 times more likely to have a severe illness (aOR 10.86, 95%CI 2.39-49.31). Patients with many comorbidities, on the other hand, had a tenfold greater chance of severe COVID-19 (aOR 9.94, 95%CI 2.47-39.88). A deficiency of vitamin D increased the chance of a serious illness by nearly five times (aOR 4.72, 95%CI 1.31-17.03).
Vitamin D level was associated with severity of illness; it can be used to estimate the prognosis of COIVD-19 patients and aid in the modification of treatment protocols.
2019年冠状病毒病（COVID-19）大流行给全球带来重创，死亡率很高。由于缺乏经证实的治疗方案，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染增加了发达国家和发展中国家的COVID-19负担。维生素D具有许多重要的抗炎、免疫调节和抗病毒功能。本研究旨在评估COVID-19患者体内维生素D之间的关系。
在印度巴特那的一家三级护理医院进行了一项横断面研究。所有患者均在3.5个月的期间内入组。使用基于化学发光的免疫分析分析仪对COVID-19患者的维生素D进行定量。该研究比较了不同组（即年龄、性别、体重指数、合并症等）之间的维生素D缺乏和不足情况。将糖尿病和高血压评估为死亡风险因素。
共调查了225名患者。其中，13.6%的患者存在维生素D缺乏，38.9%的患者存在不足。维生素D水平在不同年龄组、性别和吸烟者之间具有统计学意义。年龄>60岁的患者患重病的可能性高23倍（调整后的比值比（aOR）为23.53，95%置信区间为4.67-118.61），而年龄在40至60岁之间的患者患重病的可能性高11倍（aOR为10.86，95%置信区间为2.39-49.31）。另一方面，患有多种合并症的患者患严重COVID-19的几率高十倍（aOR为9.94，95%置信区间为2.47-39.88）。维生素D缺乏使患重病的几率增加近五倍（aOR为4.72，95%置信区间为1.31-17.03）。
维生素D水平与疾病严重程度相关；它可用于评估COVID-19患者的预后，并有助于调整治疗方案。
